Forskning ved Københavns Universitet - Københavns Universitet

Forside

Therapeutic cancer vaccines in combination with conventional therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Therapeutic cancer vaccines in combination with conventional therapy. / Andersen, Mads Hald; Junker, Niels; Ellebaek, Eva; Svane, Inge Marie; Thor Straten, Per; Andersen, Mads Hald.

I: Journal of Biomedicine and Biotechnology, Bind 2010, 01.01.2010, s. 237623.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Andersen, MH, Junker, N, Ellebaek, E, Svane, IM, Thor Straten, P & Andersen, MH 2010, 'Therapeutic cancer vaccines in combination with conventional therapy', Journal of Biomedicine and Biotechnology, bind 2010, s. 237623. https://doi.org/10.1155/2010/237623

APA

Andersen, M. H., Junker, N., Ellebaek, E., Svane, I. M., Thor Straten, P., & Andersen, M. H. (2010). Therapeutic cancer vaccines in combination with conventional therapy. Journal of Biomedicine and Biotechnology, 2010, 237623. https://doi.org/10.1155/2010/237623

Vancouver

Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P, Andersen MH. Therapeutic cancer vaccines in combination with conventional therapy. Journal of Biomedicine and Biotechnology. 2010 jan 1;2010:237623. https://doi.org/10.1155/2010/237623

Author

Andersen, Mads Hald ; Junker, Niels ; Ellebaek, Eva ; Svane, Inge Marie ; Thor Straten, Per ; Andersen, Mads Hald. / Therapeutic cancer vaccines in combination with conventional therapy. I: Journal of Biomedicine and Biotechnology. 2010 ; Bind 2010. s. 237623.

Bibtex

@article{6809acbd4bcf44c59f127ffb482892c1,
title = "Therapeutic cancer vaccines in combination with conventional therapy",
abstract = "The clinical efficacy of most therapeutic vaccines against cancer has not yet met its promise. Data are emerging that strongly support the notion that combining immunotherapy with conventional therapies, for example, radiation and chemotherapy may improve efficacy. In particular combination with chemotherapy may lead to improved clinical efficacy by clearing suppressor cells, reboot of the immune system, by rendering tumor cells more susceptible to immune mediated killing, or by activation of cells of the immune system. In addition, a range of tumor antigens have been characterized to allow targeting of proteins coupled to intrinsic properties of cancer cells. For example, proteins associated with drug resistance can be targeted, and form ideal target structures for use in combination with chemotherapy for killing of surviving drug resistant cancer cells. Proteins associated with the malignant phenotype can be targeted to specifically target cancer cells, but proteins targeted by immunotherapy may also simultaneously target cancer cells as well as suppressive cells in the tumor stroma.",
author = "Andersen, {Mads Hald} and Niels Junker and Eva Ellebaek and Svane, {Inge Marie} and {Thor Straten}, Per and Andersen, {Mads Hald}",
year = "2010",
month = "1",
day = "1",
doi = "http://dx.doi.org/10.1155/2010/237623",
language = "English",
volume = "2010",
pages = "237623",
journal = "Journal of Biomedicine and Biotechnology",
issn = "1110-7243",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - Therapeutic cancer vaccines in combination with conventional therapy

AU - Andersen, Mads Hald

AU - Junker, Niels

AU - Ellebaek, Eva

AU - Svane, Inge Marie

AU - Thor Straten, Per

AU - Andersen, Mads Hald

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The clinical efficacy of most therapeutic vaccines against cancer has not yet met its promise. Data are emerging that strongly support the notion that combining immunotherapy with conventional therapies, for example, radiation and chemotherapy may improve efficacy. In particular combination with chemotherapy may lead to improved clinical efficacy by clearing suppressor cells, reboot of the immune system, by rendering tumor cells more susceptible to immune mediated killing, or by activation of cells of the immune system. In addition, a range of tumor antigens have been characterized to allow targeting of proteins coupled to intrinsic properties of cancer cells. For example, proteins associated with drug resistance can be targeted, and form ideal target structures for use in combination with chemotherapy for killing of surviving drug resistant cancer cells. Proteins associated with the malignant phenotype can be targeted to specifically target cancer cells, but proteins targeted by immunotherapy may also simultaneously target cancer cells as well as suppressive cells in the tumor stroma.

AB - The clinical efficacy of most therapeutic vaccines against cancer has not yet met its promise. Data are emerging that strongly support the notion that combining immunotherapy with conventional therapies, for example, radiation and chemotherapy may improve efficacy. In particular combination with chemotherapy may lead to improved clinical efficacy by clearing suppressor cells, reboot of the immune system, by rendering tumor cells more susceptible to immune mediated killing, or by activation of cells of the immune system. In addition, a range of tumor antigens have been characterized to allow targeting of proteins coupled to intrinsic properties of cancer cells. For example, proteins associated with drug resistance can be targeted, and form ideal target structures for use in combination with chemotherapy for killing of surviving drug resistant cancer cells. Proteins associated with the malignant phenotype can be targeted to specifically target cancer cells, but proteins targeted by immunotherapy may also simultaneously target cancer cells as well as suppressive cells in the tumor stroma.

U2 - http://dx.doi.org/10.1155/2010/237623

DO - http://dx.doi.org/10.1155/2010/237623

M3 - Journal article

VL - 2010

SP - 237623

JO - Journal of Biomedicine and Biotechnology

JF - Journal of Biomedicine and Biotechnology

SN - 1110-7243

ER -

ID: 34133689